CIP2A is overexpressed in most human cancers, including lung, breast, colon, gastric, prostate cancers and neck and head carcinomas,14,15,44,65,66 and is inversely correlated with disease outcome in NSCLC43,67, gastric cancer66, ovarian cancer68 and chronic myeloid leukemia (CML)69. Here, CIP2A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.